NCCN Guidelines Insights: Primary Cutaneous Lymphomas, Version 2.2020

Featured Updates to the NCCN Guidelines

Restricted access

Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL), and Sézary syndrome (SS) is a rare erythrodermic and leukemic subtype of CTCL characterized by significant blood involvement. Although early-stage disease can be effectively treated predominantly with skin-directed therapies, systemic therapy is often necessary for the treatment of advanced-stage disease. Systemic therapy options have evolved in recent years with the approval of novel agents such as romidepsin, brentuximab vedotin, and mogamulizumab. These NCCN Guidelines Insights discuss the diagnosis and management of MF and SS (with a focus on systemic therapy).

  • 1.

    Bradford PT, Devesa SS, Anderson WF, . Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009;113:50645073.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Willemze R, Cerroni L, Kempf W, . The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019;133:17031714.

  • 3.

    Teras LR, DeSantis CE, Cerhan JR, . 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 2016;66:443459.

  • 4.

    Pimpinelli N, Olsen EA, Santucci M, . Defining early mycosis fungoides. J Am Acad Dermatol 2005;53:10531063.

  • 5.

    Campbell JJ, Clark RA, Watanabe R, . Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 2010;116:767771.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Olsen EA, Rook AH, Zic J, . Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol 2011;64:352404.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Diamandidou E, Colome-Grimmer M, Fayad L, . Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood 1998;92:11501159.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Vergier B, de Muret A, Beylot-Barry M, . Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. Blood 2000;95:22122218.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Arulogun SO, Prince HM, Ng J, . Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. Blood 2008;112:30823087.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Choi J, Goh G, Walradt T, . Genomic landscape of cutaneous T cell lymphoma. Nat Genet 2015;47:10111019.

  • 11.

    Kann BH, Park HS, Yeboa DN, . Annual facility treatment volume and patient survival for mycosis fungoides and Sezary syndrome. Clin Lymphoma Myeloma Leuk 2017;17:520–526, e522.

    • PubMed
    • Export Citation
  • 12.

    Olsen E, Vonderheid E, Pimpinelli N, . Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007;110:17131722.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Thurber SE, Zhang B, Kim YH, . T-cell clonality analysis in biopsy specimens from two different skin sites shows high specificity in the diagnosis of patients with suggested mycosis fungoides. J Am Acad Dermatol 2007;57:782790.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14.

    Zhang B, Beck AH, Taube JM, . Combined use of PCR-based TCRG and TCRB clonality tests on paraffin-embedded skin tissue in the differential diagnosis of mycosis fungoides and inflammatory dermatoses. J Mol Diagn 2010;12:320327.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Kirsch IR, Watanabe R, O’Malley JT, . TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. Sci Transl Med 2015;7:308ra158.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    de Masson A, O’Malley JT, Elco CP, . High-throughput sequencing of the T cell receptor β gene identifies aggressive early-stage mycosis fungoides. Sci Transl Med 2018;10:10.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17.

    Agar NS, Wedgeworth E, Crichton S, . Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 2010;28:47304739.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Talpur R, Singh L, Daulat S, . Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. Clin Cancer Res 2012;18:50515060.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Elsayad K, Kriz J, Moustakis C, . Total skin electron beam for primary cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys 2015;93:10771086.

  • 20.

    Hoppe RT, Harrison C, Tavallaee M, . Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials. J Am Acad Dermatol 2015;72:286292.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Kamstrup MR, Gniadecki R, Iversen L, . Low-dose (10-Gy) total skin electron beam therapy for cutaneous T-cell lymphoma: an open clinical study and pooled data analysis. Int J Radiat Oncol Biol Phys 2015;92:138143.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Morris S, Scarisbrick J, Frew J, . The results of low-dose total skin electron beam radiation therapy (TSEB) in patients with mycosis fungoides from the UK Cutaneous Lymphoma Group. Int J Radiat Oncol Biol Phys 2017;99:627633.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    van Doorn R, Scheffer E, Willemze R. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients. Arch Dermatol 2002;138:191198.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 24.

    Gerami P, Rosen S, Kuzel T, . Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma. Arch Dermatol 2008;144:738746.

  • 25.

    Lehman JS, Cook-Norris RH, Weed BR, . Folliculotropic mycosis fungoides: single-center study and systematic review. Arch Dermatol 2010;146:607613.

  • 26.

    Scarisbrick JJ, Prince HM, Vermeer MH, . Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and Sezary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol 2015;33:37663773.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Wieser I, Wang C, Alberti-Violetti S, . Clinical characteristics, risk factors and long-term outcome of 114 patients with folliculotropic mycosis fungoides. Arch Dermatol Res 2017;309:453459.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Hodak E, Amitay-Laish I, Atzmony L, . New insights into folliculotropic mycosis fungoides (FMF): a single-center experience. J Am Acad Dermatol 2016;75:347355.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    van Santen S, Roach RE, van Doorn R, . Clinical staging and prognostic factors in folliculotropic mycosis fungoides. JAMA Dermatol 2016;152:9921000.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 30.

    Prince HM, Kim YH, Horwitz SM, . Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 2017;390:555566.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Kim YH, Bagot M, Pinter-Brown L, . Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol 2018;19:11921204.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Duvic M, Martin AG, Kim Y, . Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001;137:581593.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Duvic M, Hymes K, Heald P, . Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001;19:24562471.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Duvic M, Talpur R, Ni X, . Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109:3139.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Olsen EA, Kim YH, Kuzel TM, . Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25:31093115.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Duvic M, Olsen EA, Breneman D, . Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 2009;9:412416.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Piekarz RL, Frye R, Turner M, . Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009;27:54105417.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Whittaker SJ, Demierre MF, Kim EJ, . Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010;28:44854491.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Kim EJ, Kim YH, Rook AH, . Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. Leuk Lymphoma 2015;56:28472854.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Horwitz SM, Kim YH, Foss F, . Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2012;119:41154122.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Foss F, Horwitz SM, Coiffier B, . Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study. Clin Lymphoma Myeloma Leuk 2012;12:238243.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Talpur R, Thompson A, Gangar P, . Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides. Clin Lymphoma Myeloma Leuk 2014;14:297304.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Kennedy GA, Seymour JF, Wolf M, . Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab. Eur J Haematol 2003;71:250256.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Lundin J, Hagberg H, Repp R, . Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003;101:42674272.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Bernengo MG, Quaglino P, Comessatti A, . Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients. Haematologica 2007;92:784794.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Alinari L, Geskin L, Grady T, . Subcutaneous alemtuzumab for Sézary syndrome in the very elderly. Leuk Res 2008;32:12991303.

  • 47.

    Querfeld C, Mehta N, Rosen ST, . Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center. Leuk Lymphoma 2009;50:19691976.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 48.

    de Masson A, Guitera P, Brice P, . Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas. Br J Dermatol 2014;170:720724.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 49.

    Khodadoust MS, Rook AH, Porcu P, . Pembrolizumab in relapsed and refractory mycosis fungoides and Sézary syndrome: a multicenter phase II study. J Clin Oncol 2020;38:2028.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Olsen EA. Interferon in the treatment of cutaneous T-cell lymphoma. Dermatol Ther 2003;16:311321.

  • 51.

    Kaplan EH, Rosen ST, Norris DB, . Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 1990;82:208212.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Zackheim HS, Kashani-Sabet M, McMillan A. Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. J Am Acad Dermatol 2003;49:873878.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    McGirt LY, Thoburn C, Hess A, . Predictors of response to extracorporeal photopheresis in advanced mycosis fungoides and Sézary syndrome. Photodermatol Photoimmunol Photomed 2010;26:182191.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Quaglino P, Knobler R, Fierro MT, . Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T-cell lymphoma: a single center clinical experience with long-term follow-up data and a brief overview of the literature. Int J Dermatol 2013;52:13081318.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 55.

    Knobler R, Berlin G, Calzavara-Pinton P, . Guidelines on the use of extracorporeal photopheresis. J Eur Acad Dermatol Venereol 2014;28(Suppl 1):137.

  • 56.

    Zinzani PL, Baliva G, Magagnoli M, . Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 2000;18:26032606.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Duvic M, Talpur R, Wen S, . Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 2006;7:5158.

  • 58.

    Jidar K, Ingen-Housz-Oro S, Beylot-Barry M, . Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 cases. Br J Dermatol 2009;161:660663.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Pellegrini C, Stefoni V, Casadei B, . Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine. Ann Hematol 2014;93:18531857.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Pulini S, Rupoli S, Goteri G, . Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas. Haematologica 2007;92:686689.

  • 61.

    Quereux G, Marques S, Nguyen JM, . Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome. Arch Dermatol 2008;144:727733.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Dummer R, Quaglino P, Becker JC, . Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol 2012;30:40914097.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 63.

    Hughes CF, Khot A, McCormack C, . Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood 2015;125:7181.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64.

    Quaglino P, Maule M, Prince HM, . Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Ann Oncol 2017;28:25172525.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65.

    Whittaker S, Ortiz P, Dummer R, . Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056). Br J Dermatol 2012;167:678687.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66.

    Duvic M, Apisarnthanarax N, Cohen DS, . Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2003;49:3549.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67.

    Straus DJ, Duvic M, Kuzel T, . Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. Cancer 2007;109:17991803.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68.

    Siakantaris MP, Tsirigotis P, Stavroyianni N, . Management of cutaneous T-Cell lymphoma patients with extracorporeal photopheresis. The Hellenic experience. Transfus Apheresis Sci 2012;46:189193.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 69.

    Duvic M, Tetzlaff MT, Gangar P, . Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol 2015;33:37593765.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Kim YH, Tavallaee M, Sundram U, . Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression level: a multi-institution collaborative project. J Clin Oncol 2015;33:37503758.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 71.

    de Masson A, Beylot-Barry M, Bouaziz JD, . Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas. Haematologica 2014;99:527534.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 72.

    Duarte RF, Boumendil A, Onida F, . Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis. J Clin Oncol 2014;32:33473348.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73.

    Lechowicz MJ, Lazarus HM, Carreras J, . Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone Marrow Transplant 2014;49:13601365.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 74.

    Hosing C, Bassett R, Dabaja B, . Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol 2015;26:24902495.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75.

    Shiratori S, Fujimoto K, Nishimura M, . Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome. Hematol Oncol 2016;34:916.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 76.

    Johnson WT, Mukherji R, Kartan S, . Allogeneic hematopoietic stem cell transplantation in advanced stage mycosis fungoides and Sézary syndrome: a concise review. Linchuang Zhongliuxue Zazhi 2019;8:12.

    • Search Google Scholar
    • Export Citation
  • 77.

    Iqbal M, Reljic T, Ayala E, . Efficacy of allogeneic hematopoietic cell transplantation in cutaneous T cell lymphoma: results of a systematic review and meta-analysis. Biol Blood Marrow Transplant 2020;26:7682.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 78.

    Duarte RF, Schmitz N, Servitje O, . Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplant 2008;41:597604.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79.

    Mori T, Shiratori S, Suzumiya J, . Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sézary syndrome [published online February 3, 2020] Hematol Oncol, doi: 10.1002/hon.2719

    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1090 1090 712
PDF Downloads 573 573 449
EPUB Downloads 0 0 0